Endo Closes on Par Pharma – Stock goes down 10%
September 28, 2015As discussed here previously, the FTC approved Endo’s acquisition of Par Pharmaceuticals last Friday, making the $8Bn deal official. The acquisition is aligned with Endo’s strategy and makes a lot of sense in terms of amplifying the company’s product portfolio, presence in…